- At doses of 150 and 300 mg, the IL-17 inhibitor secukinumab provides sustained improvements in signs and symptoms of active ankylosing spondylitis (AS) at 3-year follow-up.
Why this matters
- Clinicians should feel confident that secukinumab is a good long-term treatment option for AS.
- Prospective cohort (N=226) of patients who were initially randomly allocated to placebo or a loading dose of 10 mg/kg intravenous (IV) secukinumab followed by subcutaneous doses of 150 or 300 mg every 4 weeks.
- At 16 weeks, the placebo group was randomly allocated to the 300- or 150-mg dose groups.
- The primary outcome at week 156 was Assessment of Spondyloarthritis International Society (ASAS) improvement of at least 20% or 40% (ASAS 20/40).
- Funding: Novartis.
- Retention rates from weeks 16 to 156 were 80.5% with 300 mg and 80.9% with 150 mg.
- ASAS 20/40 at week 156:
- 68.2%/47.7% with 150 mg.
- 75.0%/56.5% with 300 mg.
- The 300-mg dose group had higher response rates than the 150-mg dose group on ASAS 40 and ASAS-PR (a score of 2 units or less in each of the 4 core ASAS domains [patient global, pain, function, and inflammation]).
- No imaging performed.